The fourth and final module of PMA application for FDA approval of Toraymyxin® has been submitted. A further data analysis of the EUPHRATES database identifies a population with significant mortality benefit when treated with Polymyxin B hemoperfusion therapy.
The SSC guidelines are built on evidence-based medicine and are the most comprehensive guidelines available for the management of sepsis and septic shock.
Polymyxin B hemoperfusion therapy is included for the first time in the SSC guidelines, reflecting that evidence is accumulating for this therapy.
EUPHRATES, an RCT performed in the USA and Canada on Polymyxin B hemoperfusion therapy (Toraymyxin®) has finished enrolment and the first results on the primary endpoints have recently been announced in a press release.
EUPHAS 2 is a web-based registry for the collection of clinical data from patients undergoing Polymyxin B hemoperfusion therapy (Toraymyxin®). Data from 357 patients recorded during the first phase have been published recently in Annals of Intensive Care Medicine.
